Table 2.

Prevalence of iatrogenic withdrawal syndrome and morbidities in the two groups

	Protocol group (n = 19)	Usual care group (n = 11)	p
Occurrence of IWS, n (%)	16 (84)	9 (81)	0.865
%Withdrawal days**	15 (9–29)	38 (17–54)	0.029*
Total weaning period (days)	12 (9–20)	11 (8–22)	1
Duration of initial phase	1 (1–3)	3 (2–4)	0.026*
Duration of tapering phase	10 (8–16)	8 (6–16)	0.605
Methadone
Average dose (mg/kg/day)	0.69 (0.45–0.85)	0.44 (0.27–1.36)	0.666
Cumulative dose (mg/kg)	6.44 (4.10–10.43)	4.23 (1.44–20.48)	0.565
Duration (days)	10 (9–18)	10 (6–19)	0.940
Lorazepam
Average dose (mg/kg/day)	0.17 (0.13–0.23)	0.22 (0.17–0.35)	0.222
Cumulative dose (mg/kg)	1.56 (1.08–3.55)	2.30 (1.73–3.82)	0.264
Duration (days)	9 (7–17)	10 (8–18)	0.707
ICU stay (days)	15 (13–34)	29 (18–43)	0.031*
Mechanical ventilation (days)	12 (9–16)	13.5 (11.5–34.5)	0.237
Adverse drug reactions, n (%)	0 (0)	1 (9.1)	0.181

Values are median (IQR), IWS, iatrogenic withdrawal syndrome; ICU, intensive care unit

^*p < 0.05

^**%withdrawal day = [withdrawal symptoms(days)/total weaning (days)] × 100%